眼科疾病治疗市场规模、份额、成长分析、按疾病适应症、按药物类别、按地区 - 产业预测，2025-2032

2023年眼疾治疗市场规模为335亿美元，从2024年的355.4亿美元成长到2032年的570.8亿美元，预测期间（2025-2032年）复合年增长率为6.10%，预计将维持在。

在眼科疾病盛行率上升和视力保健需求增加的推动下，全球眼科保健市场可望显着成长。美国国家眼科美国透露，视力相关疾病每年对美国经济造成约 1,390 亿美元的损失。各大製药公司正在大力投资视网膜疾病的创新治疗方法，预计更先进的治疗方法将在不久的将来获得核准。此外，亚洲市场上经济高效的非处方眼药的出现可能会增加全球收益。抗发炎药物、抗感染药、抗VEGF药物和抗青光眼药物占据市场主导地位，其中抗发炎药物在2019年占27%的份额，预计在预测期内将保持主导地位。

目录

介绍

• 研究目的
• 调查范围
• 定义

调查方法

• 资讯采购
• 二手资料和主要资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 按细分市场的机会分析

市场动态及展望

• 市场概况
• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制因素和挑战
• 波特的分析

主要市场考察

• 关键成功因素
• 竞争程度
• 主要投资机会
• 市场生态系统
• 市场吸引力指数（2024年）
• PESTEL分析
• 总体经济指标
• 价值链分析
• 价格分析

按药物类别分類的眼科疾病治疗市场规模

• 市场概况
• 消炎（药）
• 抗感染
• 抗VEGF
• 青光眼预防
  • β受体阻断剂
  • 前列腺素类似物
  • α肾上腺素促效剂
  • 碳酸酐酶抑制剂
  • 伴随药物
  • 其他的
• 其他的

眼疾治疗市场规模：以剂型划分

• 市场概况
• 固体的
• 液体
• 半固体

眼科疾病治疗市场规模：依疾病适应症分类

• 市场概况
• 青光眼
  • 开放性青光眼
  • 隅角闭锁性青光眼
  • 其他的
• 干眼症
• 视网膜疾病
• 糖尿病黄斑部水肿（DME）
• 黄斑部病变（AMD）
• 糖尿病视网膜病变 (DR)
• 视网膜静脉阻塞（RVO）
• 过敏及感染疾病
• 其他的

眼疾治疗市场规模：依通路划分

• 市场概况
• 医院药房
• 零售及网路药局

眼疾治疗市场规模

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地区
• 中东/非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东/非洲

竞争资讯

• 前5名企业对比
• 主要企业市场定位（2024年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市场占有率分析（2024年）
• 主要企业简介
  • 公司简介
  • 产品系列分析
  • 按细分市场分類的份额分析
  • 收益与前一年同期比较（2022-2024）

主要企业简介

• Novartis AG（Switzerland）
• Roche Holding AG（Switzerland）
• Regeneron Pharmaceuticals, Inc.（USA）
• Allergan（part of AbbVie）（USA）
• Bausch Health Companies Inc.（Canada）
• Pfizer Inc.（USA）
• Merck & Co., Inc.（USA）
• Santen Pharmaceutical Co., Ltd.（Japan）
• Teva Pharmaceutical Industries Ltd.（Israel）
• Otsuka Pharmaceutical Co., Ltd.（Japan）
• Alcon Inc.（Switzerland）
• Aerie Pharmaceuticals, Inc.（USA）
• Omeros Corporation（USA）
• Kodiak Sciences Inc.（USA）
• EyePoint Pharmaceuticals, Inc.（USA）
• Johnson & Johnson（USA）
• Abbott Laboratories（USA）
• Carl Zeiss Meditec AG（Germany）
• Topcon Corporation（Japan）
• Hoya Corporation（Japan）

结论和建议

Ophthalmic Disease Therapeutics Market size was valued at USD 33.5 Billion in 2023 and is poised to grow from USD 35.54 Billion in 2024 to USD 57.08 Billion by 2032, growing at a CAGR of 6.10% during the forecast period (2025-2032).

The global market for ophthalmic therapeutics is set for significant growth, driven by the rising incidence of ocular diseases and an escalating demand for vision care. The National Eye Institute highlights that vision-related ailments cost the U.S. economy approximately $139 billion annually. Major pharmaceutical firms are heavily investing in innovative therapies for retinal disorders, with more advanced treatments expected to gain approval in the near future. Additionally, the advent of cost-effective over-the-counter ophthalmic drugs in Asian markets is likely to boost global revenues. Anti-inflammatory, anti-infectives, anti-VEGF, and anti-glaucoma treatments dominate the market, with anti-inflammatory drugs capturing a substantial 27% share in 2019 and expected to maintain a leading position throughout the forecast period.

Top-down and bottom-up approaches were used to estimate and validate the size of the Ophthalmic Disease Therapeutics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Ophthalmic Disease Therapeutics Market Segmental Analysis

Global Ophthalmic Disease Therapeutics Market is segmented by Drug Class, Dosage Form, Disease Indication, Distribution Channel and region. Based on Drug Class, the market is segmented into anti-inflammatory, anti-infectives, Anti-VEGF, anti-glaucoma and others. Based on Dosage Form, the market is segmented into solid, liquid and semisolid. Based on Disease Indication, the market is segmented into glaucoma, dry eye disease, retinal diseases, allergy & infections and others. Based on Distribution Channel, the market is segmented into hospital pharmacies and retail & online pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Ophthalmic Disease Therapeutics Market

The growth of the ophthalmic disease therapeutics market is significantly driven by the increasing presence of small and mid-sized companies that are diversifying the competitive landscape. Key industry players, including Allergan plc, F. Hoffmann-La Roche AG, and Regeneron Pharmaceuticals, Inc., compete alongside these smaller entities, leading to a fragmented market. This competition fosters innovation and the development of new treatment options for prevalent ophthalmic conditions such as macular degeneration, macular edema, and retinal vein occlusion. Established treatments like Eylea from Regeneron and Lucentis from F. Hoffmann-La Roche continue to play pivotal roles in effectively managing these diseases, further stimulating market expansion.

Restraints in the Ophthalmic Disease Therapeutics Market

The Ophthalmic Disease Therapeutics market faces significant constraints primarily due to the extended timelines required for the manufacturing and formulation of ophthalmic medications. Additionally, the potential side effects associated with these drugs pose another challenge that could hinder market expansion during the forecast period. The complexity of developing these treatments, coupled with the need for thorough testing and regulatory approvals, often results in delays that may deter investment and innovation in this sector. Consequently, these factors are anticipated to limit the overall growth potential of the ophthalmic therapeutics market in the foreseeable future.

Market Trends of the Ophthalmic Disease Therapeutics Market

The Ophthalmic Disease Therapeutics market is witnessing a robust trend driven by rapid technological advancements in ophthalmology, particularly in imaging techniques and surgical tools that enhance patient outcomes. Innovations such as femtosecond lasers in cataract surgery exemplify the shift towards more precise and safer procedures, minimizing complications and improving recovery times. Additionally, the integration of artificial intelligence in diagnostic tools is streamlining patient assessments, allowing for earlier detection and personalized treatment approaches. As a result, these developments are attracting investment and market interest, thereby fostering growth and significantly enhancing the overall landscape of ophthalmic disease management.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Ophthalmic Disease Therapeutics Market Size by Drug Class & CAGR (2025-2032)

• Market Overview
• Anti-Inflammatory
• Anti-Infectives
• Anti-VEGF
• Anti-Glaucoma
  • Beta Blockers
  • Prostaglandins Analogs
  • Alpha Adrenergic Agonists
  • Carbonic Anhydrase Inhibitors
  • Combination Drugs
  • Others
• Others

Global Ophthalmic Disease Therapeutics Market Size by Dosage Form & CAGR (2025-2032)

• Market Overview
• Solid
• Liquid
• Semisolid

Global Ophthalmic Disease Therapeutics Market Size by Disease Indication & CAGR (2025-2032)

• Market Overview
• Glaucoma
  • Open Angle Glaucoma
  • Angle Closure Glaucoma
  • Others
• Dry Eye Disease
• Retinal Diseases
• Diabetic Macular Edema (DME)
• Macular Degeneration (AMD)
• Diabetic Retinopathy (DR)
• Retinal Vein Occlusion (RVO)
• Allergy & Infections
• Others

Global Ophthalmic Disease Therapeutics Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Hospital Pharmacies
• Retail & Online Pharmacies

Global Ophthalmic Disease Therapeutics Market Size & CAGR (2025-2032)

• North America (Drug Class, Dosage Form, Disease Indication, Distribution Channel)
  • US
  • Canada
• Europe (Drug Class, Dosage Form, Disease Indication, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Drug Class, Dosage Form, Disease Indication, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Drug Class, Dosage Form, Disease Indication, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Drug Class, Dosage Form, Disease Indication, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche Holding AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Regeneron Pharmaceuticals, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Allergan (part of AbbVie) (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bausch Health Companies Inc. (Canada)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Santen Pharmaceutical Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Otsuka Pharmaceutical Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Alcon Inc. (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aerie Pharmaceuticals, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Omeros Corporation (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kodiak Sciences Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• EyePoint Pharmaceuticals, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott Laboratories (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Carl Zeiss Meditec AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Topcon Corporation (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hoya Corporation (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations